Novel GPR52 agonists for schizophrenia / Phrenix Therapeutics

  • Stewart, Gregory (Primary Chief Investigator (PCI))
  • Langmead, Christopher (Chief Investigator (CI))
  • Nithianantharajah, Jess (Chief Investigator (CI))
  • Baell, Jonathan (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Applications for CUREator funding follow a three-stage process:
1. Expression of Interest (EOI): Interested parties with eligible projects submit a confidential EOI to the CUREator team for review.
***This Pure record is for this stage***

>>Should the EOI be success a company will be formed to receive the funds. <<
***from this stage a new company will be formed by Monash, funds will be deposited into this company***
2. Full Application: Successful EOI applicants will be requested to prepare a full application.
3. Due Diligence and execution: Successful full applications will work with the CUREator team to complete due diligence.
Effective start/end date1/06/22 → …